- Home
- WMPN vs CUE Comparison
WMPN vs CUE Comparison
Compare WMPN & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WMPN
- CUE
- Stock Information
- Founded
- WMPN 1870
- CUE 2014
- Country
- WMPN United States
- CUE United States
- Employees
- WMPN N/A
- CUE N/A
- Industry
- WMPN Savings Institutions
- CUE Biotechnology: Pharmaceutical Preparations
- Sector
- WMPN Finance
- CUE Health Care
- Exchange
- WMPN Nasdaq
- CUE Nasdaq
- Market Cap
- WMPN 104.2M
- CUE 94.4M
- IPO Year
- WMPN N/A
- CUE 2018
- Fundamental
- Price
- WMPN $12.00
- CUE $1.32
- Analyst Decision
- WMPN
- CUE Strong Buy
- Analyst Count
- WMPN 0
- CUE 5
- Target Price
- WMPN N/A
- CUE $5.00
- AVG Volume (30 Days)
- WMPN 16.1K
- CUE 195.8K
- Earning Date
- WMPN 04-16-2025
- CUE 03-10-2025
- Dividend Yield
- WMPN 1.00%
- CUE N/A
- EPS Growth
- WMPN N/A
- CUE N/A
- EPS
- WMPN N/A
- CUE N/A
- Revenue
- WMPN $20,363,000.00
- CUE $9,532,000.00
- Revenue This Year
- WMPN N/A
- CUE $73.11
- Revenue Next Year
- WMPN N/A
- CUE $11.02
- P/E Ratio
- WMPN N/A
- CUE N/A
- Revenue Growth
- WMPN N/A
- CUE 149.53
- 52 Week Low
- WMPN $10.80
- CUE $0.45
- 52 Week High
- WMPN $13.87
- CUE $2.37
- Technical
- Relative Strength Index (RSI)
- WMPN 38.02
- CUE 48.32
- Support Level
- WMPN $12.44
- CUE $1.22
- Resistance Level
- WMPN $12.75
- CUE $1.54
- Average True Range (ATR)
- WMPN 0.26
- CUE 0.11
- MACD
- WMPN -0.05
- CUE -0.01
- Stochastic Oscillator
- WMPN 0.00
- CUE 35.29
About WMPN William Penn Bancorporation
William Penn Bancorporation operates as an independent community financial services provider. The bank offers traditional banking and related financial services to individual, business, and government customers. Through its branch and automated teller machine network, the bank offers a full array of commercial and retail financial services, including; the taking of time, savings, and demand deposits; the making of commercial, consumer, and mortgage loans; and the providing of other financial services.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.